A detailed history of Verus Capital Partners, LLC transactions in Amgen Inc stock. As of the latest transaction made, Verus Capital Partners, LLC holds 2,908 shares of AMGN stock, worth $763,786. This represents 0.09% of its overall portfolio holdings.

Number of Shares
2,908
Previous 3,015 3.55%
Holding current value
$763,786
Previous $942,000 0.64%
% of portfolio
0.09%
Previous 0.09%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

SELL
$309.38 - $337.38 $33,103 - $36,099
-107 Reduced 3.55%
2,908 $936,000
Q2 2024

Aug 01, 2024

BUY
$262.75 - $319.31 $207,835 - $252,574
791 Added 35.57%
3,015 $942,000
Q1 2024

May 07, 2024

BUY
$268.87 - $324.56 $17,745 - $21,420
66 Added 3.06%
2,224 $632,000
Q4 2023

Feb 09, 2024

BUY
$255.7 - $288.46 $14,830 - $16,730
58 Added 2.76%
2,158 $621,000
Q3 2023

Nov 01, 2023

SELL
$218.65 - $271.46 $4,373 - $5,429
-20 Reduced 0.94%
2,100 $564,000
Q2 2023

Jul 31, 2023

BUY
$214.27 - $253.37 $7,713 - $9,121
36 Added 1.73%
2,120 $470,000
Q1 2023

May 09, 2023

SELL
$225.79 - $275.2 $3,386 - $4,128
-15 Reduced 0.71%
2,084 $503,000
Q4 2022

Feb 14, 2023

BUY
$229.03 - $291.01 $13,283 - $16,878
58 Added 2.84%
2,099 $551,000
Q3 2022

Nov 14, 2022

SELL
$224.46 - $253.15 $6,958 - $7,847
-31 Reduced 1.5%
2,041 $460,000
Q2 2022

Aug 09, 2022

SELL
$230.71 - $256.74 $16,611 - $18,485
-72 Reduced 3.36%
2,072 $504,000
Q1 2022

Aug 09, 2022

BUY
$219.27 - $242.57 $186,818 - $206,669
852 Added 65.94%
2,144 $512,000
Q1 2020

May 26, 2020

BUY
$182.24 - $241.7 $9,112 - $12,085
50 Added 4.03%
1,292 $262,000
Q4 2019

Feb 27, 2020

BUY
$189.21 - $243.2 $234,998 - $302,054
1,242 New
1,242 $299,000

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $140B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Verus Capital Partners, LLC Portfolio

Follow Verus Capital Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Verus Capital Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Verus Capital Partners, LLC with notifications on news.